First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.

Viscuse, Paul V; Price, Katharine A; Garcia, Joaquin J; Schembri-Wismayer, David J; Chintakuntlawar, Ashish V

Viscuse, Paul V; Price, Katharine A; Garcia, Joaquin J; Schembri-Wismayer, David J; Chintakuntlawar, Ashish V.

Afiliação

Viscuse PV; Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
Price KA; Division of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
Garcia JJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Schembri-Wismayer DJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Chintakuntlawar AV; Division of Medical Oncology, Mayo Clinic, Rochester, MN, United States.

Front Oncol ; 9: 701, 2019.

Article em En | MEDLINE | ID: mdl-31428578

Palavras-chave

adenocarcinoma; androgen deprivation therapy; androgen receptor; head and neck cancer; metastatic cancer; salivary duct carcinoma; salivary gland cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article